Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
INTERVIEW
Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
Takeda Pharmaceutical has moved to establish a joint venture with Teva Pharmaceutical Industries. Teva Takeda Pharma, in which Takeda will have a 49% stake, and its subsidiary Teva Takeda Yakuhin will handle Takeda’s long-listed drugs and generics. What was the…
To read the full story
Related Article
- Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
INTERVIEW
- Interview: Mathematician Changing the Future of Drug Discovery (FRONTEO CTO)
March 25, 2025
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
February 2, 2021
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…